REFERENCES
- Riordan T.G.O. Inhaled antimicrobial therapy: From cystic fibrosis to the flu. Respir. Care 2000; 45(7)836–845, [CSA]
- Lode H. Tobramycin: A review of therapeutic uses and dosing schedules. Curr. Ther. Res 1998; 59(7)420–453, [CSA], [CROSSREF]
- Eisenberg J., Pepe M., Williams-Warren J., Vasiliev M., Montgomery A.B., Smith A.L., Ramsey B.W. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems and the Aerosolized Tobramycin Study Group. Chest 1997; 111: 955–962, [INFOTRIEVE], [CSA]
- Taylor K.M.G., Pancholi K., Wong D.Y.T. In vitro evaluation of DPI formulations of micronized and milled nedocromil sodium. Pharm. Pharmacol. Comm 1999; 5: 255–257, [CSA]
- Clarke M.J., Tobyn M.J., Staniforth J.N. The formulation of powder inhalation systems containing a high mass of nedocromil sodium trihydrate. J. Pharm. Sci 2001; 90(2)213–223, [INFOTRIEVE], [CSA], [CROSSREF]
- De Boer A.H., Le Brun P.P.H., Van der Woude H.G., Hagedoorna P., Heijerman H.G.M., Frijlink H.W. Dry powder inhalation of antibiotics in cystic fibrosis therapy. 1. Development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur. J. Pharm. Biopharm 2002; 54: 17–24, [INFOTRIEVE], [CSA], [CROSSREF]
- Bechtold-Peters K., Nguyen H., Rowley G. Surface modification of powders with fatty acid or fatty alcohol derivatives or poloxamer for inhalation. PCT Int. Appl 2002, 20021017[CSA]
- Ikegami K., Kawashima Y., Takeuchi H., Yamamoto H., Mimura K., Momose D., Ouchi K. A new agglomerated KSR-592 ß-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J. Control. Rel 2003; 88: 23–33, [CSA], [CROSSREF]
- Vanbever R., Mintzes J., Wan J., Nice J., Chen D., Batycky R., Langer R., Edwards D. A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res 1999; 16: 1735–1742, [INFOTRIEVE], [CSA], [CROSSREF]
- Bennet T.N., Weitz J.B., Edwards D.A. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. USA 2002; 99(19)12001–12005, [CSA], [CROSSREF]
- Lee K., Gould G. Aerogel powders for inhalation therapy. PCT Int. Appl 2002, 2002 0704[CSA]
- Maa Y.F., Nguyen P.A., Sweeney T., Shire S.J., Hsu C. Protein inhalation powders: spray drying vs spray freeze drying. Pharm. Res 1999; 16: 249–254, [INFOTRIEVE], [CSA], [CROSSREF]
- Tarara T., Weers J., Dellamary L. R.N. Dalby, P. R. Byron, S.J. Farr, J. PeartEngineered powders for inhalation. Respiratory Drug Delivery VII, . Serentec Press, Raleigh, NC 2000; 2: 413, (1)
- Chew N.Y.K., Chan H.K. Use of solid corrugated particles to enhance aerosol performance. Pharm. Res 2001; 18: 1570–1577, [INFOTRIEVE], [CSA], [CROSSREF]
- Bhavane R., Karathanasis E., Annapragada A.V. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J. Control. Rel 2003; 93: 15–28, [CSA], [CROSSREF]
- Steckel H., Brandes H.G. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm 2004; 278: 187–195, [INFOTRIEVE], [CSA], [CROSSREF]
- Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., Weers J.G. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 2003; 124: 360–366, [INFOTRIEVE], [CSA], [CROSSREF]
- Bosquillon C., Véronique P., Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Rel 2004; 96: 233–244, [CSA], [CROSSREF]
- Bosquillon C., Lombry C., Véronique P., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Rel 2001; 70: 329–339, [CSA], [CROSSREF]
- Upasani R.S., Banga A.K. Response surface methodology to investigate the iontophoretic delivery of tacrine hydrochloride. Pharm. Res 2004; 21(12)2293–2299, [INFOTRIEVE], [CSA], [CROSSREF]
- Hwang K.T., Jung S.T., Lee G.D., Chinnan M.S., Park Y.S., Park H.J. Controlling molecular weight and degree of deacetylation of chitosan by response surface methodology. J. Agr. Food Chem 2002; 50: 1876–1882, [CSA], [CROSSREF]
- Karachi A.A., Khan M.A. Box-Behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. Int. J. Pharm 1996; 131: 9–17, [CSA], [CROSSREF]
- Singh S.K., Reddy I.K., Khan M.A. Optimization and characterization of controlled release pellets coated with an experimental latex: II. Cationic drug. Int. J. Pharm 1996; 141: 179–195, [CSA], [CROSSREF]
- Sastry S.V., Reddy I.K., Khan M.A. Atenolol gastrointestinal therapeutic system: Optimization of formulation variables using response surface methodology. J. Control. Rel 1997; 45: 121–130, [CSA], [CROSSREF]
- Chew N.Y.K., Chan H.-K. Effect of powder polydispersibility on aerosol generation. J. Pharm. Pharm. Sci 2002; 5(2)162–168, [INFOTRIEVE], [CSA]
- 26. Monographs; Tobramycin. United States Pharmacopoeia 27. 2004, CD-ROM.
- 27. Physical tests and determination; aerosols. United States Pharmacopoeia 27. 2004, CD-ROM.
- Lucas P., Anderson K., Potter U.J., Staniforth J.N. Enhancement of small particle size dry powder aerosol formulations using ultra low density additive. Pharm. Res 1999; 16(10)1643–1647, [INFOTRIEVE], [CSA], [CROSSREF]
- Hickey A.J., Martonen T.B., Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm. Acta. Helv 1996; 71: 185–190, [INFOTRIEVE], [CSA], [CROSSREF]
- Niven R., editor. Dry powder formulations for inhalation. Adv. Drug Deliv. Rev 1997; 26(special)1–67, [INFOTRIEVE], [CSA], [CROSSREF]
- Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing. J. Aerosol Med 1993; 6: 99–110, [INFOTRIEVE], [CSA]